It is an appropriate time to bring together the various groups working in the UK on markers of breast and ovarian cancer. Physicians are interested in the problems of how to use markers for screening, management of advanced disease and increasing imaging and therapy targeting. These main areas of interest formed the basis of the sessions allocated for paper presentation and discussion.
Screening (Chairman Dr. J.E. Roulston) Scott (Derby) presented the rationale for screening of ovarian cancer. Ovarian cancer fulfils the World Health Organisation definitions for a tumour which should be considered for screening. It has an incidence of about 4,000 cases per annum in England and Wales (and including Scotland about 4,500 cases). It is a major health problem being the commonest cause of death from gynaecological cancer and the increase in incidence is faster than that for breast cancer Imaging and molecular investigation (Chairman Dr R. Leonard) Sikora (London) gave an overall view of radio immunoscintigraphy in cancer management and pointed out the deficiencies as well as the benefits of targeting tumour cell proteins for diagnosis and management.
Steel (Edinburgh) reviewed chromosomal and genetic changes in EOC and breast cancer. DNA ploidy is a useful guide to prognosis in both tumours, but particularly in borderline EOC. Multiple specific chromosome aberrations have been reported in both diseases and there are almost too many to be of individual clinical value. Oncogene over expression characterises both breast and ovarian cancer, particularly erb B2, ras and myc oncogenes. Work in the tumour suppressor gene area has also produced some interesting specific information on deletions and there are parallels between breast and ovarian cancer but also probably some very important differences.
Barnes (London) gave some practical guidelines for the assaying of primary tumour tissues with antibodies, particulary for fixed paraffin-embedded sections. There are problems with prognostic factor studies and prognostic factor evaluation has to be based on biological hypothesis. A pilot study which looks promising requires to be confirmed by a definitive study. This demands careful calculation of the sample size and allowance made for the likely bias in the patient population selected. Careful validation of the methodology need to be made and optimal cutoff values defined before the study is performed. Ultimately the value of such tissue markers will depend upon their reproducibility.
Britten (London) gave a very positive overview of current imaging techniques with monoclonals for ovarian cancer. He emphasised the value of small amounts of antibody for imaging (around +-1 mg), and the great advantages of being able to use technetium (Tc9) scanning which allows a current widely available equipment to be utilised as opposed to the earlier iodine 123 or indium 111 scans. Imaging over time is important. A 10 min image is a template followed by images at 6 h and 24 h to provide subtraction scan pictures. Also kinetic analysis can be performed on the digital information from the scan which will give greater confidence in the differences from baseline. The antibodies which are successful for targeting ovarian cancer include SM3, HMFG2 HMFG,. The accuracy for detecting pelvic undiagnosed masses is around 97% and relative uptake for the antibody in malignant vs benign tissues is of the order of 30:1 to 170:1 depending on the antibody. It is important to get a good signal allowing the statistical processing can deal with the background noise.
Therapy (Chaiman Professor P. Porter) Epenetos (London) gave a resume of the targeting studies with immunotherapy in ovarian cancer. He emphasised the possibilities of molecular design in improving the functional characteristics of antibody and was optimistic about the benefit of targeted therapy in a limited number of clinical situations, particularly where there is small amount of remaining disease.
Verhoeyen (Bedford) discussed the modification of murine monoclonals into humanised forms by genetic engineering. One such antibody (HMFG1) which is relevant for targeting ovarian cancer is now being manufactured in therapeutic quantities. Sharma (London) described the use of the ADEPT system of primary antibody linked to pro-drug followed by secondary antibody with enzyme link to activated the pro-drug at the target site. Work has commenced in the clinic having refined the system in laboratory animals. One problem has been to deal with the human antibody mouse antibody (HAMA) and this has been achieved by enhancing in the clearance of the HAMA by a secondary exposure to an non specific mouse antibody. There is no convincing evidence yet that the ADEPT system has produced improved targeting in the clinic although the laboratory data look quite promising.
Dr Leonard concluded the conference by emphasising the positive clinical work that is now emerging particularly in the area of serum monitoring and radio diagnosis.
The majority of these papers are due to be published in full in 'Disease Markers'.
